title: Potential inhibitory effect of LASSBio-596, a new thalidomide hybrid, on inflammatory corneal angiogenesis in rabbits.
abstract: OBJECTIVE
  Evaluate the effect of LASSBio-596, structurally designed as a new hybrid of thalidomide, on inflammatory corneal angiogenesis.
  
  
  METHODS
  Eighteen rabbits were submitted to an alkaline cauterization in the right cornea. The animals were randomly allocated to three groups: vehicle, dexamethasone and LASSBio-596. Drugs were administered by eyedrops 3 times a day for 21 days. Evaluations were performed on days 3, 6, 9, 12, 15, 18 and 21 after cauterization. At these time points, digital images of the cornea were captured in a standard fashion. The angiogenic response was measured using software that was developed specifically for this purpose. It calculated the following parameters: neovascularization area (NA), total vascular length (TVL) and blood vessel number (BVN).
  
  
  RESULTS
  It was observed that dexamethasone significantly decreased NA, TVL and BVN during all assessments. From the NA the angiogenesis rate (AR) was calculated in each group. Therefore, dexamethasone completely inhibited the inflammatory corneal angiogenesis with an AR of -0.001 ± 0.006 mm(2)/day, which was significantly lower (p < 0.001) than that observed after treatment with vehicle (0.078 ± 0.024 mm(2)/day) and LASSBio-596 (0.054 ± 0.012 mm(2)/day). Although LASSBio-596 reduced angiogenesis in relation to vehicle, according to NA, TVL and BVN values, this difference was not statistically significant. However, it was found that the AR as measured in the LASSBio-596 group was significantly lower (p < 0.05) than that seen in control animals, indicating a potential antiangiogenic effect.
  
  
  CONCLUSIONS
  We conclude that topical application of LASSBio-596 at 1.0% has a potential inhibitory effect on inflammatory corneal angiogenesis in rabbits.
authors: Universidade Federal do Ceara, Ceara, Brazil. jcmlribeiro@gmail.com
authors: Joao Crispim M L
authors: JC
authors: Ribeiro
authors: Francisco
authors: F
authors: Vagnaldo Fechine
authors: Mariana Zaira M L
authors: MZ
authors: Ribeiro
authors: Eliezer J
authors: EJ
authors: Barreiro
authors: Lidia Moreira
authors: LM
authors: Lima
authors: Nagila M P S
authors: NM
authors: Ricardo
authors: Maria Elisabete
authors: ME
authors: Amaral de Moraes
authors: Manoel
authors: M
authors: Odorico de Moraes
mesh_terms: D000818:Animals; D016510:Corneal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D003907:Dexamethasone / Q000494:pharmacology; D004195:Disease Models, Animal; D005938:Glucocorticoids / Q000494:pharmacology; D007634:Keratitis / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009883:Ophthalmic Solutions; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D010795:Phthalic Acids; D010797:Phthalimides / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D011817:Rabbits; D013449:Sulfonamides; D013792:Thalidomide / Q000737:chemistry*
chemical_list: D005938:Glucocorticoids; C514420:LASSBIO596; D009883:Ophthalmic Solutions; D010726:Phosphodiesterase Inhibitors; D010795:Phthalic Acids; D010797:Phthalimides; D013449:Sulfonamides; D013792:Thalidomide; D003907:Dexamethasone